Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-006912
Filing Date
2025-11-14
Accepted
2025-11-14 13:33:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 14428
2 d12040025_ex99-a.htm EX-35 9456
3 d12040025_ex99-b.htm EX-99 775
  Complete submission text file 0000919574-25-006912.txt   26385
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90539 | Film No.: 251484062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201
Business Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201 214-550-1822
Avidity Partners Management LP (Filed by) CIK: 0001791827 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A